Engineered Extracellular Vesicles As a New Delivery Platform for Migraine

Migraine represents a complex neurovascular disorder that is challenging to treat due to the blood-brain barrier (BBB) and complex pathophysiology involving the trigeminovascular system, neuroinflammation, and cortical spreading depression. Current systemic therapies, including calcitonin gene-related peptide (CGRP) inhibitors, offer benefits but have limited efficacy and may cause adverse effects; thus, highlighting the need for targeted delivery across the BBB. This review introduces extracellular vesicles (EVs) as an appropriate pharmaceutical engineering platform to address such challenges. While traditional treatments have inherent disadvantages, engineered EVs offer efficient blood-brain barrier (BBB) penetration, targeted delivery, and multi-therapeutic payload capacity for migraine-associated neural circuits. We introduce a framework for pathophysiology-informed technology by first discussing the role of native EVs in promoting the migraine cascade to identify specific sites of therapeutic intervention. In this review, the focus is on pharmaceutical nanotechnology, starting with the strategic selection of producer cells, including "Hijack & Modify" vs De Novo Design, and continuing through sequential nano-engineering of EVs by surface functionalization and utilization of hybrid vesicles for targeting the BBB and trigeminovascular systems to state-of-the-art smart-release systems. We continue with the critical analytical and manufacturing sciences needed to translate such engineered EVs from bench to bedside, addressing important translational challenges through scalable Good manufacturing practices (GMP) production, supported potency assays, and comprehensive quality assurance processes. These include potency tests, GMP production, and robust quality control that may be expanded. Finally, we combine all of these into a single translational pathway that examines the regulatory issues, the patent landscape, and the future of personalized EV therapeutics. The current review provides an exhaustive framework for developing EV-based treatments by combining cutting-edge pharmaceutical nanotechnology with deep biological insights to make migraine treatment more reliable.